The Patient in 2035: What Could a Day of Healthcare Look Like? Clarus Biotech Review A fictional day asks what earlier detection, personalized treatment, and connected care would need to deliver for a real person. At 7:15 a.m., Maya closes her health app and makes breakfast. The reassuring part of her morning is not the amount of data on the screen. It is that someone has already decided which information deserves her attention. Maya is fictional. So is this day in 2035. It is a scenario for examining what better healthcare would require, not a forecast or a treatment recommendation. Its most ambitious proposition is deceptively ordinary: more useful care, with less work imposed on the person receiving it. Morning: a signal becomes a conversation In this imagined system, a change in Maya’s measurements prompts a clinician to review her history. An isolated alert does not automatically trigger a diagnosis or a new medicine. The team first asks whether the signal is reliable, whether it changes a decision, and whether acting now is likely to help. Earlier detection makes an appealing promise, but finding an abnormality is only the beginning. NCI explains that multi-cancer detection tests identify signals that may suggest cancer; they do not establish a diagnosis. The usefulness of screening also depends on the workup that follows and the availability of effective care. A more sensitive test is therefore not, by itself, proof that a screening program improves patient outcomes. [1] For Maya, the practical innovation would be a named professional who explains the result, arranges necessary follow-up, and tells her when no further action is appropriate. A future with more alerts but no additional clinical capacity could feel less like prevention and more like permanent uncertainty. Midday: personalized enough to matter At her appointment, Maya’s treatment discussion starts with the disease, her circumstances, and evidence from people relevant to her situation. “Personalized” does not mean every patient needs a unique drug. It might mean choosing an established treatment more accurately, adjusting how it is delivered, or avoiding an intervention unlikely to help. There are more radical possibilities. In May 2025, NIH described a patient-specific gene-editing treatment for an infant with CPS1 deficiency. The report described early clinical improvement after a therapy designed around that child’s mutation. This was a striking individual case, not evidence that customized editing is broadly effective, durable, or ready for routine use across diseases. [2] In our 2035 scenario, the question for a delivery platform is concrete: can it reach the relevant tissue with a reproducible product, an acceptable safety profile, and a monitoring burden the patient can manage? A beautiful molecular design cannot answer those questions alone. Each proposed application needs its own evidence. Afternoon: the distance between eligibility and access Maya’s clinician recommends a treatment. The next questions concern where it can be given, who pays, how much time away from work is required, and who will help if she feels unwell. This is where a technologically impressive future could remain an uneven one. The CMS Cell and Gene Therapy Access Model provides a present-day example of an attempt to connect access and payment: its initial focus is sickle cell disease, with an approach that links payment arrangements to outcomes. It should be evaluated as an access initiative, not treated as proof that every logistical or financial barrier has disappeared. [3] A useful 2035 access standard would measure completed care. Consider an entirely invented planning example: 1,000 potentially eligible people, 70% completing diagnostic confirmation, and 60% of that group reaching treatment. The result is 420 treatment starts. These percentages are assumptions, not observed rates. The example shows why the size of an eligible population cannot substitute for the number of people actually served. Evening: less work for the patient At home, Maya has one clear plan. She knows which symptoms require contact, which measurements matter, and how to reach a human being. The system shares the necessary information with her permission. It also offers a workable alternative if she cannot or does not want to use an app. The editorial test is simple: did the technology return time, confidence, or function to the patient? A program that lowers clinic visits while transferring hours of unpaid coordination to a family has not necessarily reduced the burden of care. What would have to be true? Signals would need to improve decisions, with benefits and harms measured in the intended population. Personalization would need dependable manufacturing and application-specific safety evidence. Clinical teams would need the capacity and payment arrangements to act on results. Access would need to work across geography, language, income, disability, and digital preferences. Patients would need meaningful control over data and an understandable route to human help. Three horizons, three different claims Horizon What this article means Established foundations Clinical interpretation, diagnostic confirmation, evidence-based treatment selection, and follow-up remain essential. Emerging possibilities Patient-specific editing and new screening approaches raise promising questions that require further validation. Speculative integration Maya’s seamless 2035 day is an imagined service model, not a demonstrated system or a promised timeline. The future worth building is not defined by how many technologies fit into a patient’s day. It is defined by how much better that day becomes. Sources https://prevention.cancer.gov/research-areas/networks-consortia-programs/csrn/q-a-about-mcd-tests https://www.nih.gov/news-events/news-releases/infant-rare-incurable-disease-first-successfully-receive-personalized-gene-therapy-treatment https://www.cms.gov/priorities/innovation/innovation-models/cgt Original article: https://www.clarusreview.bio/articles/the-patient-in-2035